Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-19T06:36:08.325Z Has data issue: false hasContentIssue false
  • English
  • Français

Eye disease in older people

Published online by Cambridge University Press:  31 July 2013

Robert MJ Purbrick ,
John J Ah-Chan  and
Susan M Downes
Robert MJ Purbrick
Affiliation:
Oxford Eye Hospital, John Radcliffe Hospital, Oxford
John J Ah-Chan
Affiliation:
MidCentral DHB Palmerston North Hospital, Palmerston North, New Zealand
Susan M Downes*
Affiliation:
Oxford Eye Hospital, John Radcliffe Hospital, Oxford
*
Address for correspondence: Susan M. Downes, Oxford Eye Hospital, West Wing, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Age-related changes affect all structures of the eye, and while age-related changes may influence the quality of vision, it is important to distinguish age-related physiological changes from pathological changes. This is important particularly when identifying pathological changes that may be treatable. The prevalence of visual loss increases substantially after 60 years of age and poor vision is the second most prevalent physical disability in older people. This review describes the normal ageing changes of the eye and outlines common ophthalmic diseases affecting older people. We refer to recent advances in diagnosis and treatment, and relevant current research.

Keywords

ageingeyevision disordersmacular degeneration
Type
Review Article
Information
Reviews in Clinical Gerontology , Volume 23 , Issue 3 , August 2013 , pp. 234 - 250
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Klein, R, Klein, BE, Linton, KL, De Mets, DL. The Beaver Dam Eye Study: visual acuity. Ophthalmology 1991; 98: 1310.CrossRefGoogle ScholarPubMed
2Gohdes, DM, Balamurugan, A, Larsen, BA, Maylahn, C. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005; 2: A17.Google ScholarPubMed
3Dening, TOMR, Chi, L-Y, Brayne, C, Huppert, FAet al.Changes in self-rated health, disability and contact with services in a very elderly cohort: a 6-year follow-up study. Age and Ageing 1998; 27: 23–33.CrossRefGoogle Scholar
4RNIB – Key information and statistics. 2012. Available at: http://www.rnib.org.uk/aboutus/research/statistics/Pages/statistics.aspx (accessed 12 March 2012.Google Scholar
5Sheldrick, JH, Wilson, AD, Vernon, SA, Sheldrick, CM. Management of ophthalmic disease in general practice. Br J General Practice 1993; 43: 459.Google ScholarPubMed
6Damasceno, RW, Osaki, MH, Dantas, PE, Belfort, R. Involutional entropion and ectropion of the lower eyelid: prevalence and associated risk factors in the elderly population. Ophthal Plast Reconstr Surg 2011; 27: 317–20.CrossRefGoogle ScholarPubMed
7Mitchell, P, Hinchcliffe, P, Wang, JJ, Rochtchina, E, Foran, S. Prevalence and associations with ectropion in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2001; 29: 108–10.CrossRefGoogle Scholar
8Sridharan, GV, Tallis, RC, Leatherbarrow, B, Forman, WM. A community survey of ptosis of the eyelid and pupil size of elderly people. Age Ageing 1995; 24: 21.CrossRefGoogle ScholarPubMed
9Love, LP, Farrior, EH. Periocular anatomy and aging. Facial Plast Surg Clin North Am 2010; 18: 411–17.CrossRefGoogle ScholarPubMed
10Ding, J, Sullivan, DA. Aging and dry eye disease. Exp Gerontol 2012; 47: 483–90.CrossRefGoogle ScholarPubMed
11Bourne, WM, Nelson, LR, Hodge, DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci 1997; 38: 779–82.Google Scholar
12Niederer, RL, Perumal, D, Sherwin, T, McGhee, CN. Age‐related differences in the normal human cornea: a laser scanning in vivo confocal microscopy study. Br J Ophthalmol 2007; 91: 1165.CrossRefGoogle Scholar
13Moseley, I. Spots before the eyes: a prevalence and clinicoradiological study of senile scleral plaques. Clini Radiol 2000; 55: 198–206.CrossRefGoogle ScholarPubMed
14Birren, JE, Casperson, RC, Botwinick, J. Age changes in pupil size. J Gerontol 1950; 5: 216–21.CrossRefGoogle ScholarPubMed
15Fotiou, DF, Brozou, CG, Tsiptsios, DJ, Fotiou, Aet al.Effect of age on pupillary light reflex: evaluation of pupil mobility for clinical practice and research. Electromyogr Clin Neurophysiol 2007; 47: 11–22.Google ScholarPubMed
16Jonas, JB, Nangia, V, Gupta, R, Sinha, A, Bhate, K. Lens thickness and associated factors. Clin Experiment Ophthalmol 2012; 40: 583–90.CrossRefGoogle ScholarPubMed
17Pointer, JS. The presbyopic add. II. Age-related trend and a gender difference. Ophthalmic Physiol Opt 1995; 15: 241–48.CrossRefGoogle Scholar
18Pascolini, D, Mariotti, SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96: 614–18.CrossRefGoogle ScholarPubMed
19Minassian, D, Reidy, A. Future sight loss UK (2): An epidemiological and economic model for sight loss in the decade 2010–2020. Full report prepared by EpiVision for the Royal National Institute for the Blind (2009).Google Scholar
20Mukesh, BN, Le, A, Dimitrov, PN, Ahmed, Set al.Development of cataract and associated risk factors: the Visual Impairment Project. Arch Ophthalmol 2006; 124: 79–85.CrossRefGoogle ScholarPubMed
21Jaycock, P, Johnston, RL, Taylor, H, Adams, Met al.The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. Eye (Lond) 2009; 23: 38–49.CrossRefGoogle ScholarPubMed
22Agresta, B, Knorz, MC, Kohnen, T, Donatti, C, Jackson, D. Distance and near visual acuity improvement after implantation of multifocal intraocular lenses in cataract patients with presbyopia: a systematic review. J Refract Surg 2012; 28: 426–35.CrossRefGoogle ScholarPubMed
23Weber-Krause, B, Eckardt, C. [Incidence of posterior vitreous detachment in the elderly]. Ophthalmologe 1997; 94: 619–23.CrossRefGoogle ScholarPubMed
24Klein, R, Klein, BE, Jensen, SC, Meuer, SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997; 104: 7–21.CrossRefGoogle ScholarPubMed
25Farkas, TG, Sylvester, V, Archer, D. The ultrastructure of drusen. Am J Ophthalmol 1971; 71: 1196–205.CrossRefGoogle ScholarPubMed
26Nag, TC, Wadhwa, S. Ultrastructure of the human retina in aging and various pathological states. Micron 2012; 43: 759–81.CrossRefGoogle ScholarPubMed
27Bunce, C, Xing, W, Wormald, R. Causes of blind and partial sight certifications in England and Wales: April 2007 – March 2008. Eye (Lond) 2010; 24: 1692–99.CrossRefGoogle ScholarPubMed
28Economics, A. Future sight loss UK: The economic impact of partial sight and blindness in the UK adult population. UK: RNIB (2009).Google Scholar
29Klein, RJ, Zeiss, C, Chew, EY, Tsai, JYet al.Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385–89.CrossRefGoogle ScholarPubMed
30Haines, JL, Hauser, MA, Schmidt, S, Scott, WKet al.Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 419–21.CrossRefGoogle ScholarPubMed
31Edwards, AO, Ritter III, R, Abel, KJ, Manning, Aet al.Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421–24.CrossRefGoogle ScholarPubMed
32Donoso, LA, Kim, D, Frost, A, Callahan, A, Hageman, G. The role of inflammation in the pathogenesis of age-related macular degeneration. Survey Ophthalmol 2006; 51: 137–52.CrossRefGoogle Scholar
33Algvere, PV, Marshall, J, Seregard, S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006; 84: 4–15.CrossRefGoogle ScholarPubMed
34Clemons, TE, Milton, RC, Klein, R, Seddon, JMet al.Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 19. Ophthalmology 2005; 112: 533–39.Google ScholarPubMed
35Rudnicka, AR, Jarrar, Z, Wormald, R, Cook, DGet al.Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012; 119: 571–80.CrossRefGoogle ScholarPubMed
36Christen, WG, Schaumberg, DA, Glynn, RJ, Buring, JE. Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women. Arch Ophthalmol 2011; 129: 921–29.CrossRefGoogle ScholarPubMed
37van Leeuwen, R, Boekhoorn, S, Vingerling, JR, Witteman, JCMet al.Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294: 3101–7.CrossRefGoogle ScholarPubMed
38Rosenfeld, PJ, Brown, DM, Heier, JS, Boyer, DSet al.Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–31.CrossRefGoogle ScholarPubMed
39Brown, DM, Kaiser, PK, Michels, M, Soubrane, Get al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–44.CrossRefGoogle ScholarPubMed
40Gragoudas, ES, Adamis, AP, Cunningham, ET, Feinsod, Met al.Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–16.CrossRefGoogle ScholarPubMed
41Regillo, CD, Brown, DM, Abraham, P, Yue, Het al.Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239–48.CrossRefGoogle ScholarPubMed
42Fung, AE, Lalwani, GA, Rosenfeld, PJ, Dubovy, SRet al.An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566–83.CrossRefGoogle ScholarPubMed
43IVAN Study Investigators, Chakravarthy, U, Harding, SP, Rogers, CA, Downes, SM, Lotery, AJ, Wordworth, S, Reeves, BC. Ranibizumab versus bevacizumab to treat neovascular age related macular degeneration: one year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399–411.CrossRefGoogle ScholarPubMed
44National Institute for Clinical Excellence. Pegaptanib and ranibizumab for the treatment of age-related macular degeneration. 2008. Available at: http://guidance.nice.org.uk/TA155 (accessed 3 October 2012).Google Scholar
45Sunness, JS, Margalit, E, Srikumaran, D, Applegate, CAet al.The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007; 114: 271–77.CrossRefGoogle ScholarPubMed
46Chew, EY, Clemons, T, Sangiovanni, JP, Danis, Ret al.The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 Report Number 1). Ophthalmology 2012; 119: 2282–89.CrossRefGoogle ScholarPubMed
47Schmitz-Valckenberg, S, Mössner, A, Fleckenstein, M, Wiedemann, P, Holz, FG. [Therapy approaches for geographic atrophy]. Ophthalmologe 2010; 107: 1016–19.CrossRefGoogle ScholarPubMed
48Reynolds, R, Hartnett, ME, Atkinson, JP, Giclas, PCet al.Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009; 50: 5818–27.CrossRefGoogle ScholarPubMed
49Zhu, D, Deng, X, Xu, J, Hinton, DR. What determines the switch between atrophic and neovascular forms of age related macular degeneration? – the role of BMP4 induced senescence. Aging (Albany NY) 2009; 1: 740–45.CrossRefGoogle ScholarPubMed
50King, H, Aubert, RE, Herman, WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–31.CrossRefGoogle ScholarPubMed
51Klein, R, Klein, BEK, Moss, SE, Davis, MD, DeMets, DL. The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527.CrossRefGoogle ScholarPubMed
52Fletcher, EC, Chong, V. The impact of national diabetic retinopathy screening on ophthalmology: the need for urgent planning. Eye 2006; 20: 1424–25.CrossRefGoogle ScholarPubMed
53Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102: 647–61.CrossRefGoogle Scholar
54Stratton, IM, Cull, CA, Adler, AI, Matthews, DRet al.Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761–69.CrossRefGoogle ScholarPubMed
55Bailey, CC, Sparrow, JM, Grey, RHB, Cheng, H. The national diabetic retinopathy laser treatment audit III. Clinical outcomes. Eye 1999; 13: 151–59.CrossRefGoogle ScholarPubMed
56 [No authors listed]. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108: 958–64.CrossRefGoogle Scholar
57Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761–74.CrossRefGoogle Scholar
58Luttrull, JK, Dorin, G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 2012; 8: 274–84.CrossRefGoogle ScholarPubMed
59Bonini-Filho, MA, Jorge, R, Barbosa, JC, Calucci, Det al.Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005; 46: 3845–49.CrossRefGoogle ScholarPubMed
60Meyer, CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007; 221: 118–31.CrossRefGoogle ScholarPubMed
61Rajendram, R, Fraser-Bell, S, Kaines, A, Michaelides, Met al.A 2-year prospective randomized controlled trial of intravitreal Bevacizumab or Laser Therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3. Arch Ophthalmol 2012; 130: 972–79.CrossRefGoogle ScholarPubMed
62Elman, MJ, Qin, H, Aiello, LP, Beck, RWet al.Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312–18.CrossRefGoogle ScholarPubMed
63Mitchell, P, Bandello, F, Schmidt-Erfurth, U, Lang, GEet al.The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–25.CrossRefGoogle ScholarPubMed
64Nguyen, QD, Shah, SM, Heier, JS, Do, DVet al.Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009; 116: 2175–81.CrossRefGoogle Scholar
65Massin, P, Bandello, F, Garweg, JG, Hansen, LLet al.Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399–405.CrossRefGoogle ScholarPubMed
66Wong, TY, Larsen, EK, Klein, R, Mitchell, Pet al.Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005; 112: 540–47.CrossRefGoogle ScholarPubMed
67Haller, JA, Bandello, F, Belfort, R, Blumenkranz, MSet al.Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134–46.CrossRefGoogle ScholarPubMed
68Campochiaro, PA, Heier, JS, Feiner, L, Gray, Set al.Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102–12.CrossRefGoogle ScholarPubMed
69Brown, DM, Campochiaro, PA, Singh, RP, Li, Zet al.Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124–33.CrossRefGoogle ScholarPubMed
70Cheng, H.Emergency Ophthalmology: a Symptom Based Guide to Diagnosis and Early Management. BMJ Publishing Group, London, 1997.Google Scholar
71Patrono, C, García Rodríguez, LA, Landolfi, R, Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373–83.CrossRefGoogle ScholarPubMed
72Mitchell, P, Smith, W, Attebo, K, Healey, PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661–69.CrossRefGoogle ScholarPubMed
73The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–40.CrossRefGoogle Scholar
74Leske, MC, Heijl, A, Hussein, M, Bengtsson, Bet al.Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48–56.CrossRefGoogle ScholarPubMed
75Lichter, PR, Musch, DC, Gillespie, BW, Guire, KEet al.Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943–53.CrossRefGoogle ScholarPubMed
76Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995; 120: 718–31.CrossRefGoogle Scholar
77Rüfer, F, Schröder, A, Klettner, A, Frimpong-Boateng, Aet al.Anterior chamber depth and iridocorneal angle in healthy White subjects: effects of age, gender and refraction. Acta Ophthalmol 2010; 88: 885–90.CrossRefGoogle ScholarPubMed
78Friedman, DS, Foster, PJ, Aung, T, He, M. Angle closure and angle-closure glaucoma: what we are doing now and what we will be doing in the future. Clin Experiment Ophthalmol 2012; 40: 381–87.CrossRefGoogle Scholar
79Schulzer, M. Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. Ophthalmology 1992; 99: 1468–70.CrossRefGoogle Scholar
80Kass, MA, Heuer, DK, Higginbotham, EJ, Johnson, CAet al.The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–13; discussion 829–30.CrossRefGoogle ScholarPubMed
81Pollock, A, Hazelton, C, Henderson, CA, Angilley, Jet al.Interventions for visual field defects in patients with stroke. Cochrane Database Syst Rev 2011; CD008388.Google ScholarPubMed
82Felson, DT, Anderson, JJ, Hannan, MT, Milton, RCet al.Impaired vision and hip fracture. The Framingham Study. J Am Geriatr Soc 1989; 37: 495–500.CrossRefGoogle ScholarPubMed
83Rees, G, Fenwick, EK, Keeffe, JE, Mellor, D, Lamoureux, EL. Detection of depression in patients with low vision. Optom Vis Sci 2009; 86: 1328–36.CrossRefGoogle ScholarPubMed
84McCarty, CA, Nanjan, MB, Taylor, HR. Vision impairment predicts 5 year mortality. Br J Ophthalmol 2001; 85: 322–26.CrossRefGoogle ScholarPubMed
85Zheng, DD, Christ, SL, Lam, BL, Arheart, KLet al.Increased mortality risk among the visually impaired: the roles of mental well-being and preventive care practices. Invest Ophthalmol Vis Sci 2012; 53: 2685–92.CrossRefGoogle ScholarPubMed